​Roka Bioscience (ROKA) Adding Automation to the Food Safety Industry

Bolton Flautt  |

Roka Bioscience (ROKA) has been active on the airwaves of late having announced and effected a one-for-ten reverse stock split, and also the company announced that it is presenting at the Sidoti MicroCap Conference on November 1 in New York. Roka Bioscience has a market capitalization of $117.17 million; a 52-week range between $0.50 and $7.37; and an average daily volume of 321,218 shares. The company was founded in 2009; headquartered in Warren, New Jersey; and has 90 full time employees.

Roka Bioscience will be one of 60 companies in the microcap universe presenting at the MicroCap Conference. Conferences are a good place for small companies to spread their message. There will be many microcap investors and industry professionals mingling and swapping business cards so there should be quite a buzz coming out of Hotel Monaco just before Halloween.

Also, as previously mentioned by Roka Bioscience, they effected a one-for-ten reverse stock split to satisfy the minimum listing price of $1.00 per share for the Nasdaq exchange. After the split, the outstanding common stock of Roka Bioscience was reduced from 17.8 million to 1.8 million shares.

Fundamentally, Roka Bioscience is a revenue producing company and for its most recent announced quarter ended June 30, 2016, the company announced revenue of $1.8 million compared to $1.5 million for corresponding quarter in 2015, or a 20 percent increase YOY. Commenting on the second quarter 2016 results, Mary Duseau, Roka’s Senior Vice President and Chief Commercial Officer, stated, “We believe the increased attention to food safety from regulators, consumers and the food industry supports the strong position held by Roka with our highly accurate pathogen tests and automated Atlas® platform. We are seeing the impact of this renewed focus on better food safety programs as we continue to grow volume of both our new Atlas Listeria Environmental Assay, as well as our other assays."

Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include molecular tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin- producing E.coli, and Listeria monocytogenes, as well as related consumable supplies. It serves food processors, third-party contract testing laboratories, and government regulatory authorities.

Follow this company at the Sidoti Emerging Growth Convention

November 1st, 2016
Marriott Marquis in Times Square
New York, NY

Click here for more info

For details regarding participation or sponsorship opportunities please contact:
email:Conference Coordinator Phone: 212-453-7031

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change






INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup

Equities.com Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.